威高股份(01066.HK)中期純利升3.5%至9.70億元 中期息0.062元。
格隆匯 8 月 26日丨威高股份(01066.HK)公佈,截至2020年6月30日止6個月,集團收入約為人民幣50.91億元,同比增加約3.0%;股東應占純利約為人民幣9.70億元,同比增加約3.5%,每股盈利為人民幣0.22元,擬派中期股息每股人民幣0.062元。
期間內,臨牀護理業務錄得營業額約為人民幣18.61億元,較同期下降10.4%,主要是受新冠疫情影響;未來期間,集團會持續豐富產品組合,憑藉公司強大的規模實力,繼續於該領域市場保持優勢地位。
期間內,藥品包裝業務錄得營業額約為人民幣7.65億元,較去年同期增長22.1%,仍保持強勁增長勢頭。預充式注射器進一步擴大在生物製藥包裝領域的市場影響力,形成廣泛客户基礎。
期間內,骨科業務錄得營業額約為人民幣8.31億元,較去年同期增長21.8%,通過進一步鞏固在脊柱領域的市場地位、加大關節產品市場推廣,以及渠道下沉、搭建物流平台等措施,較好的拉動銷售增長。
期間內,介入業務錄得營業額約為人民幣7.83億元,較去年同期下降3.7%,主要是受到國外疫情影響,未來期間,集團將通過內部資源共享擴大愛琅產品在中國市場的銷售。
基於產品結構戰略性調整的要求,集團繼續保持在現有產品系列和多個新醫療器械領域的研發投入,以進一步完善醫療器械細分領域的產品組合。截至2020年6月30日止六個月,研發的總開支約為人民幣1.43億元,佔集團收入的2.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.